Spero Therapeutics, Inc. SPRO
1.02 USD +0.01 (+0.99%)
At closeNov 11, 2026, 4:55 PM EST
1.01 -0.01 -0.95%
After hours · Nov 11, 4:55 PM ET
1.01 Day range 1.05
0.961 52-week range 3.08
- YTD
- -56.22%
- 1 year
- -61.07%
News
globenewswire.com Spero Therapeutics Appoints William Ho, M.D., Ph.D., to its Board of Directors CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients…
globenewswire.com Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in…
globenewswire.com Spero Therapeutics to Present at Investor Conferences in November CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in…
benzinga.com This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday Analysts initiated bullish coverage on Rubrik, Kardigan, MSG Rangers and Ormat Technologies, with price targets of $155, $50, $257 and $123.
benzinga.com This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Analysts initiated coverage: Hold ALHC; Overweight/$6 SPRO; Buy/$3 LABT; Buy/$6 CLOV.
benzinga.com Cantor Fitzgerald Initiates Coverage On Spero Therapeutics with Overweight Rating, Announces Price Target of $6 Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Spero Therapeutics (NASDAQ:SPRO) with a Overweight rating and announces Price Target of $6.
globenewswire.com Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline Amy Rock, Ph.D., appointed Chief Regulatory and Quality Officer, bringing extensive experience in global regulatory strategy, clinical development, and with approvals of novel immunotherapies Dae Gon…
marketbeat.com Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related Disease Spero Therapeutics NASDAQ: SPRO plans to initiate a Phase II trial of its lead immunology candidate, SP001, in immunoglobulin G4-related disease, or IgG4-RD, in the second quarter of 2027, Chief…
globenewswire.com Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology…
invezz.com Russian plague outbreak could boost these under-the-radar pharma stocks Global biosecurity alarms are flashing after an incident at an anti-plague research facility in Siberia sparked a severe public health response. Following the fatal lab exposure of a researcher in…
globenewswire.com Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology…
benzinga.com Meta Platforms To $650? Here Are 10 Top Analyst Forecasts For Monday Analysts raised price targets for Meta, IREN, Coinbase, Roblox and others; IREN and Coinbase were upgraded, while other ratings held steady.- benzinga.com HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $6 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spero Therapeutics (NASDAQ:SPRO) with a Buy and raises the price target from $5 to $6.
globenewswire.com Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology…
globenewswire.com Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology…
seekingalpha.com Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript
marketbeat.com Spero Therapeutics Q2 Earnings Call Highlights Spero Therapeutics NASDAQ: SPRO used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for…
globenewswire.com Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology…
globenewswire.com Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology…
globenewswire.com Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology…
globenewswire.com Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer Dr. Zack brings more than 25 years of leadership in developing therapeutics for immune-mediated diseases Appointment strengthens Spero's clinical leadership team as the Company advances SP001, a…
seekingalpha.com Spero Therapeutics: 'Buy' On Utebzi Royalty Deal For Funding And SP001 In-Licensing Spero Therapeutics is initiated with a "Buy" rating, driven by its strategic pivot to immunology and strong non-dilutive financing. SPRO secured FDA approval for Utebzi and a $105M royalty deal,…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals…- benzinga.com Spero Therapeutics Announces $105M In Non-Recourse Non-Dilutive Royalty Financing With KKR's Healthcare Royalty Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent BiologicsTransaction unlocks immediate value from future Utebzi (tebipenem pivoxil)…
- benzinga.com Spero Therapeutics Enters License Agreement With Innovent Biologics For Exclusive Rights To Develop, Research, Manufacture, And Commercialize SP001 Globally Ex-China Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355)Innovent will receive an…
globenewswire.com Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology…
prnewswire.com Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize IBI355 (Spero R&D code: SP001) Innovent…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating earnings and revenue estimates. Other gainers include LNKS, ADTX, and SPRO.- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs FDA approves GSK and SPRO's Utebzi, the first oral carbapenem for cUTIs. Launch planned for late 2026. See market reaction.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com GSK, Spero Therapeutics Announce FDA Approves Utebzi To Treat Complicated Urinary Tract Infections https://www.gsk.com/en-gb/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adults-with-complicated-urinary-tract-infections-cutis/
benzinga.com Spero Therapeutics Q1 EPS $(0.13) Beats $(0.18) Estimate, Sales $258.000K Down From $5.874M YoY Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 48 percent increase over losses of…
benzinga.com Earnings Scheduled For May 13, 2026 - benzinga.com Earnings Scheduled For March 26, 2026
- benzinga.com Earnings Scheduled For November 13, 2025
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Earnings Scheduled For August 12, 2025
benzinga.com Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Crude Oil Gains 2%; Macy's Lowers Earnings Forecast 
benzinga.com US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Earnings Scheduled For May 13, 2025
- benzinga.com Earnings Scheduled For March 27, 2025
benzinga.com Earnings Scheduled For November 14, 2024